ILNS in The News


  Intellect Neurosciences chases Holy Grail of Alzheimer's: a preventive vaccine
FierceVaccines - April 10, 2012

  Intellect Neurosciences is the Quiet Force Behind the Next Generation of Alzheimer’s disease Therapies
CEOCFO - April 6, 2012

  Intellect Neurosciences CEO Predicts ‘We are Less than 5 Years from Alzheimer’s Disease-Modifying Drugs’
ACCESSWIRE - September 15, 2010

  Big player at Wyeth and Pfizer joins ILNS as Alzheimer's pipeline draws attention
TradingMarkets.com - September 10, 2010

  Ex-Pfizer scientist consulting for firm
theday.com - September 9, 2010

  Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease
The Medical News - August 18, 2010

  Intellect Neurosciences receives patent for insulin sensitizer drugs
The Medical News - August 12, 2010

  Intellect Neurosciences receives patent for Alzheimer's disease vaccine
The Medical News - August 11, 2010

  Canada Issues NOA For Intellect Neurosciences OX1
Pharmaceutical Business Review - August 9, 2010

  Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada
The Medical News - August 9, 2010

  Alzheimer's epidemic will follow the obesity one
ZDNet - July 15, 2010

  An Alzheimer's cure could be closer than we think
ZDNet - June 30, 2010

  Intellect Neurosciences, Inc. Receives Notice of Allowance for Patent on Alzheimer’s Drug From the Israeli Patent and Trademark Office
Intellectual Property Today - June 9, 2010